Erythropoietin Stimulating Agents Policies

CMS has policies that effect the use of Erythropoietin Stimulating Agents in ESRD facilities. To find out more, click on the links below.

Downloads
ESA Monitoring Policy, Effective October 1, 2006 [PDF, 151 KB] ESA Monitoring Policy, Effective April 1, 2006 [PDF, 173 KB] Medicare Benefit Policy Manual, Chapter 11, End Stage Renal Disease (ESRD) - Section 90 – Epoetin (EPO) [PDF, 347KB] Medicare Claims Processing Manual, Chapter 8 – Outpatient ESRD Hospital, Independent Facility and Physician/Supplier Claims - Section 60.4 – Epoetin Alfa (EPO) and Section 60.7 – Darbepoetin Alfa (Aranesp) for ESRD Patients [PDF, 625KB]
Related Links Inside CMS
ESA Monitoring Policy, Effective January 1, 2008 NCD for ESAs for in Cancer and Related Neoplastic Conditions -  CAG-00383N Coverage Center Medicare Coverage Database
Related Links Outside CMS
There are no Related Links Outside CMS

Page Last Modified: 06/02/2010 9:27:59 AM
Help with File Formats and Plug-Ins